Russell Devore Iii, MD

home / authors / russell-devore-iii-md

Articles

Weekly Irinotecan and Concurrent Radiation Therapy for Stage III Unresectable NSCLC

Hak Choy, MD;Anuradha Chakravarthy, MD;Russell Devore Iii, MD;Madan Jagasia, MD;Kenneth R. Hande, MD;John R. Roberts, MD;David H. Johnson, MD;Furhan Yunus, MD

July 2nd 2000

In preclinical studies, the topoisomerase I inhibitor irinotecan (Camptosar, CPT-11) has demonstrated activity as a radiosensitizer, probably due to its ability to inhibit potentially lethal radiation damage repair. We conducted a

Irinotecan Plus Cisplatin in Patients With Advanced Non- Small-Cell Lung Cancer

Russell Devore Iii, MD;David Johnson, MD;Jeffrey Crawford, MD;Isaiah Dimery, MD;John Eckardt, MD;S. Gail Eckhardt, MD

August 1st 1998

During the 1980s, platinum-based regimens were yielding response rates typically less than 25%, median survival durations of about 25 weeks, and 1-year survival rates less than 25% in patients with advanced non-small-cell lung